Report Highlights
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
Report Includes
- 37 data tables and 55 additional tables
- An updated review of the global market for chimeric antigen receptor (CAR) T-cell therapy with emphasis on the current research and development status
- Analyses of the global market trends, with historic data from 2018-2020, estimates for 2021 and 2022, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation and forecast the overall CAR T-Cell therapy market size in dollar value terms, and corresponding market share analysis by product, application, technology and region
- Highlights of the market potential for the CAR T-cell therapy market, opportunities and trends estimating current and future demand, and impact of COVID-19 on the progress of this market
- Assessment of current marketed drugs, including development activities, R&D activities and anticipated developments, along with a look into the patent expirations within the industry
- Latest information on the major stakeholders of global CAR T-Cell therapy market, along with a review of their intellectual property status, product innovations, technological advancements, and research collaborations and business consolidations
- Insight into the current competitive environment, recent mergers and acquisitions, license agreements, and company revenue share analysis of the key players involved in the development of therapeutics for CAR T-cell therapy
- Descriptive company profiles of the leading industry players, including AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Novartis AG, F. Hoffmann-La Roche and Takeda Pharmaceutical Co., Ltd.
Report Scope
The key objectives of this study are to:
- Review the historical development of CAR T-cell technology.
- Discuss the principles of chimeric antigen receptor design.
- Understand the mechanisms of action associated with CAR T-cell immunotherapy.
- Highlight the ongoing clinical and non-clinical advancements in the field of CAR T-cell therapy.
- Access the side effects, disadvantages and limitations of existing CAR T-cell technologies.
- Examine the current marketed drugs, including development activities and details of patent expirations.
- Determine the production methods for CAR T-cells.
- Review the range of joint ventures, collaborations, license and research agreements currently focused on CAR T-cell technology.
- Review of the regulatory requirements.
- Review the global CAR T-cell therapy market dynamics.
- Survey the key players involved in the development of therapeutics for CAR T-cell immunotherapy and provide company profiles.
By purchasing this study, the reader will gain:
- An improved understanding of the current state and future of this exciting, new and innovative technology.
- The latest information on the leading companies engaged in developing this technology, clinical trials being conducted, a review of the status of their intellectual property, product pipelines and insight into their proprietary technologies.
- The role and influence of individual countries relating to the development of CAR T-cell therapy and the number of CAR T-cell trials in the U.S. versus China and other countries.
- Knowledge of the market potential for the CAR T-cell therapy market and anticipated development of the market.
The analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, an analysis of the incidence and mortality associated with cancers and the target market helps provide the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Molecular Farming: Global Markets (CHM187A)
- Exosome Diagnostics, Therapeutics and Research Tools: Global Markets (BIO149E)
- Global Skin Allergy Testing Market (MDS104A)
- Global Aircraft Recycling Market (AVM250A)
- Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets (HLC078F)
Report Highlights
The global market for Chimeric Antigen Receptor (CAR) T-cell therapies will grow from nearly $467.0 million in 2018 to $2.9 billion by 2023 at a compound annual growth rate (CAGR) of 44.1% for the period of 2018-2023.
Report Includes
- 31 data tables and 41 additional tables
- An overview of global market for current research & developments status of Chimeric Antigen Receptor (CAR) T-cell therapy
- Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Understand market dynamics of CAR T-Cell therapy, along with the growth driving factors, restraints and future scope
- Information on competitor initiatives, research and development status of CAR T-cell therapy
- Comprehensive company profiles of major players in the market including, Amgen, Avacta Life Sciences Ltd., Bluebird Bio Inc., Novartis Ag, Servier Laboratories, Takeda Pharmaceuticals, and Transgene SA
Related Reports
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Flow Cytometry: Products, Technologies and Global Markets
The global market for flow cytometry is estimated to increase from $5.2 billion in 2022 to reach $7.6 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs should grow from $126.7 billion in 2021 to $208.6 billion by 2026 with a compound annual growth rate (CAGR) of 10.5% for the period of 2021-2026.
Biological Therapies for Cancer: Technologies and Global Markets
The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
Recent Reports
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Viral Vector and Plasmid DNA: Technologies and Global Markets
The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Flame Retardant Chemicals: Technologies and Global Markets
The global consumption of flame retardant chemicals is estimated to grow from 6.0 billion pounds in 2022 to 7.5 billion pounds in 2027, at a compound annual growth rate (CAGR) of 4.4% for the period of 2022-2027.
Biorefinery Products: Global Markets
The global market for biorefinery products is estimated to increase from $624.7 billion in 2022 to $920.0 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Electric Vehicle Charging: Infrastructure and Global Markets
The global market for wired electric vehicle charging infrastructure is estimated to grow from $24.1 billion in 2022 to $81.1 billion in 2027, at a compound annual growth rate (CAGR) of 27.4% for the period of 2022-2027.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More